Hormone replacement therapy (HRT) during the menopause can alleviate symptoms such as hot flushes, osteoporosis and sleep disturbances. In addition, HRT can also prevent diseases or – as initial studies suggest – reduce COVID-19 mortality. A team of researchers led by Martin Wildschwendter at the University of Innsbruck has now demonstrated that combined HRT (progesterone and oestrogen) also slows the ageing of epithelial cells (the basic building blocks of many tissues) after the menopause. However, this benefit was not observed in women with breast cancer. For the study, the research team analysed over 2,000 samples taken regularly by gynaecologists during screening examinations as part of cervical smear tests. The research group’s findings were made possible by their discovery of a new ‘epigenetic clock’, known as the WID-REA clock. This is a molecular biology test that analyses typical ‘ageing’ markers on the DNA. This allows the ageing of cells to be determined and a person’s age to be estimated to within a few years. The rate of cellular ageing is linked to an increased risk of disease and higher mortality from certain conditions, including cancer. “The current study demonstrates the enormous potential of epigenetic clocks as a source of information about our biological age,” says lead author Chiara Herzog: “As gynaecologists, we therefore need tests that enable us to measure ageing processes and tailor anti-ageing strategies – such as hormone replacement therapy, but also exercise and diet – to the individual needs of each woman. The test can also be used to determine which women would benefit from a slowing of cellular ageing through HRT and how health-promoting measures could be individually tailored.” Reference: University of Innsbruck. ‘Susceptibility to hormone-mediated cancer is reflected by different ticking rates of the epithelial and general epigenetic clock’, Gen Biol 2022; https://doi.org/10.1186/s13059-022-02603-3
Hormone replacement therapy slows down cellular ageing